stockrowExicure, Inc.
XCUR Healthcare Biotechnology
Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022.
- EPS
- +56.1%
- Free cash flow
- +65.4%
Quarter to June 2026, against a year earlier
Follow XCUR
Alert me
Exicure, Inc. (XCUR) EV/Sales
As of 6 November 2026, Exicure, Inc. (XCUR) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −35.8× (March 2020) to 1,114× (May 2019); the current reading is higher than 16% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 0.9× | 386.55% |
| FY2022 | 0.2× | (98.78%) |
| FY2021 | 14.4× | 168.77% |
| FY2020 | 5.4× | (88.24%) |
| FY2019 | 45.5× | (95.84%) |
| FY2018 | 1,095× | 7,492.60% |
| FY2017 | 14.4× | 0.00% |
| FY2016 | 14.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2024 | 0.4× | 155.59% |
| Dec 2022 | 0.2× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | −1.4× | — |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −71.4× |
| APRE Aprea Therapeutics, Inc. compare | −34.8× |
| EVGN Evogene Ltd. compare | −3.6× |
| LGVN Longeveron Inc. compare | −3.1× |
| CRIS Curis, Inc. compare | −0.3× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| XCUR Exicure, Inc. | 0.2× |
| ORGS Orgenesis Inc. compare | 16.9× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)